

November 2, 2020

SymBio Pharmaceuticals Limited

Fuminori Yoshida

Representative Director,

President and Chief Executive Officer

**Monthly Exercise Status of the 51st Stock Acquisition Rights (with Exercise Price Revision Clauses)
Issued by way of Third Party Allotment**

TOKYO, Japan, November 2, 2020- SymBio Pharmaceuticals Limited announces the monthly exercise status for October of 51st Stock Acquisition Rights issued and allotted to EVO FUND on March 16, 2020.

(1) Name of stock acquisition rights	SymBio Pharmaceuticals Limited 51 st Stock Acquisition Rights
(2) Number of shares delivered for the month	100,000 Shares
(3) Number of stock acquisition rights exercised during the month and exercise ratio to the total number of stock acquisition rights issued	100,000 Units (Ratio to total 3,000,000 Units Issued : 3.3%)
(4) Number of unexercised stock acquisition rights as of the exercise start day	3,000,000 Units
(5) Number of unexercised stock acquisition rights at the end of the month	2,900,000 Units

(6) Exercise Status for respective month

Exercise Date	Number of shares issued		Exercise Price (¥)	Number of stock acquisition rights exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
October 14 (Wed)	-	-	388	-
October 15 (Thu)	-	-	388	-
October 16 (Fri)	-	-	388	-
October 19 (Mon)	-	-	388	-
October 20 (Tue)	-	-	388	-
October 21 (Wed)	-	-	359	-
October 22 (Thu)	-	-	359	-
October 23 (Fri)	-	-	359	-
October 26 (Mon)	-	-	359	-
October 27 (Tue)	-	-	359	-
October 28 (Wed)	100,000	-	343	100,000
October 29 (Thu)	-	-	343	-
October 30 (Fri)	-	-	343	-

※Number of issued shares at the end of the previous month : 35,198,331 shares [of which 26,543 shares are treasury shares]

(7) Status concerning restriction on exercise (Status concerning compliance with exercise restrictions under Article 434 of the Listing Regulations)

① Total number of shares to be delivered upon the exercise of all series of stock acquisition rights	② Number of listed shares at the time of the payment for the issuance	③ Exercise ratio on exercise limit(①/②)
100,000 Shares	28,122,581 Shares	0.36%

For further details regarding this issuance, please refer to “Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)” published on February 27, 2020.